Stock comparison
Eli Lilly
Rigel Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
RIGL
Rigel Pharmaceuticals
Market cap
$536.75M
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | RIGL | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 47D | LLY |
| Benjamin Graham | 86A | 34F | LLY |
| Philip Fisher | 86A | 54C | LLY |
| Peter Lynch | 74B | 54C | LLY |
| Joel Greenblatt | 78C | 48D | LLY |
| Charlie Munger | 85A | 62D | LLY |
| Terry Smith | 77C | 61C | LLY |
Side-by-side metrics
| Metric | LLY | RIGL |
|---|---|---|
| Market cap | $1T | $536.75M |
| P/E (TTM) | 36.6x | 1.4x |
| EV/EBIT | 34.1x | 4.3x |
| ROIC (TTM) | 32.06% | 27.96% |
| Gross margin | 83.51% | 93.39% |
| Net margin | 34.98% | 121.51% |
| Revenue CAGR 5y | 23.17% | 18.5% |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | 0.1x |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $536.75M+100%
- Revenue CAGR 5y23.17%vs 18.5%+20%
- ROIC (TTM)32.06%vs 27.96%+13%
RIGL leads on
- P/E (TTM)1.4xvs 36.6x+96%
- Debt / Equity0.1xvs 1.4x+92%
- EV/EBIT4.3xvs 34.1x+87%
- Net margin121.51%vs 34.98%+71%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.